Modality
Multispecific
MOA
RAS(ON)i
Target
Tau
Pathway
Complement
Parkinson'sPBCEpilepsy
Development Pipeline
Preclinical
~Sep 2010
→ ~Dec 2011
Phase 1
~Mar 2012
→ ~Jun 2013
Phase 2
~Sep 2013
→ ~Dec 2014
Phase 3
~Mar 2015
→ ~Jun 2016
NDA/BLA
~Sep 2016
→ ~Dec 2017
Approved
Mar 2018
→ Jul 2029
ApprovedCurrent
NCT03869387
2,527 pts·Parkinson's
2023-06→2029-07·Completed
NCT06174540
1,823 pts·PBC
2018-03→2026-02·Not yet recruiting
NCT06977001
2,768 pts·Parkinson's
2022-05→TBD·Terminated
+1 more trial
8,475 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2026-02-241mo agoPh3 Readout· PBC
2027-02-1611mo awayPh3 Readout· Parkinson's
2029-07-193.3y awayPh3 Readout· Parkinson's
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Not yet…
Approved
Active
Approved
Termina…
Approved
Complet…
Catalysts
Ph3 Readout
2026-02-24 · 1mo ago
PBC
Ph3 Readout
2027-02-16 · 11mo away
Parkinson's
Ph3 Readout
2029-07-19 · 3.3y away
Parkinson's
ActiveCompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03869387 | Approved | Parkinson's | Completed | 2527 | PANSS |
| NCT06174540 | Approved | PBC | Not yet recr... | 1823 | Safety |
| NCT06977001 | Approved | Parkinson's | Terminated | 2768 | OS |
| NCT04615807 | Approved | Parkinson's | Active | 1357 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| 180-3597 | Innovent Bio | Preclinical | SHP2 | |
| CGO-2579 | CG Oncology | Approved | TIGIT |